Bedaquiline-Pretomanid-Linezolid Regimens Compared for XDR TB
FRIDAY, Sept. 16, 2022 (HealthDay News) -- For patients with extensively drug-resistant (XDR) tuberculosis, the overall risk-benefit ratio seems to favor patients receiving the bedaquiline-pretomanid-linezolid regimen with linezolid at a dose of 600 mg for 26 weeks, according to a study published in the Sept. 1 issue of the New England Journal of Medicine.
Francesca Conradie, M.B., B.Ch., from the University of the Witwatersrand in Johannesburg, South Africa, and colleagues enrolled participants with XDR tuberculosis, pre-XDR tuberculosis, or rifampicin-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued due to side effects. Participants were randomly assigned to receive bedaquiline for 26 weeks, pretomanid, and daily linezolid at a dose of 1,200 mg for 26 weeks or nine weeks or 600 mg for 26 weeks or nine weeks. One hundred eighty-one participants were enrolled.
The researchers found a favorable outcome for 93, 89, 91, and 84 percent of those receiving bedaquiline-pretomanid-linezolid with linezolid at a dose of 1,200 mg for 26 weeks or nine weeks or 600 mg for 26 weeks or nine weeks, respectively; peripheral neuropathy occurred in 38, 24, 24, and 13 percent, respectively; and myelosuppression occurred in 22, 15, 2, and 7 percent, respectively. In 51, 30, 13, and 13 percent of participants, the linezolid dose was modified (i.e., interrupted, reduced, or discontinued). In four participants (9 percent) who had received linezolid at a dose of 1,200 mg for 26 weeks, optic neuropathy developed.
"A 600-mg, 26-week regimen of linezolid appeared to have the most favorable risk-benefit profile among the regimens studied," the authors write.
Editorial (subscription or payment may be required)
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Related Posts
Later School Start Times Boost Parents’ Health, Too
TUESDAY, Jan. 11, 2022 (HealthDay News) -- For several years, a leading U.S....
Las ‘recetas de productos agrícolas’ ahorrarían 40 mil millones en facturas médicas a los diabéticos: estudio
JUEVES, 13 de julio de 2023 (HealthDay News) -- Quizá una cantidad generosa de...
Las máscaras N-95 son indispensables para la ómicron, pero hay muchas falsificaciones
JUEVES, 30 de diciembre de 2021 (HealthDay News) -- Mientras ve cómo la variante...
U.S. Pregnancy Deaths Drop Following Spike During Pandemic
THURSDAY, March 16, 2023 (HealthDay News) -- After U.S. pregnancy deaths soared...